# A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

> **NCT05572684** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NextCure, Inc.** · enrollment: 97 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Microsatellite Instability Low
- Microsatellite Instability High
- Microsatellite Stable
- Ovarian Cancer
- Gastric Cancer
- Colo-rectal Cancer
- Esophageal Cancer
- Endometrial Cancer
- Head Neck Cancer
- Cervical Cancer
- Lung Cancer

## Interventions

- **DRUG:** NC410
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT05572684
- **Lead sponsor:** NextCure, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-06
- **Primary completion:** 2025-07
- **Final completion:** 2025-11
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2024-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05572684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05572684, "A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05572684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*